Fundraising Fox
/Companies
Sign in

Satellos

Toronto · Founded 2021 · 1 known investors

Find your way into Satellos

Sign up to see every warm intro you have to Satellos

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Satellos team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Satellos is a biotechnology company developing oral small molecule therapies that restore the body's natural muscle regeneration process by targeting muscle stem cell asymmetric division. Its lead candidate, forazapadin, targets degenerative muscle diseases, beginning with Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy (FSHD).

BiotechMedical Devices

Founders & leadership

FB
Franklin BergerNamed on SEC filing
FG
Frank GleesonNamed on SEC filing
MR
Michael Robert CrossNamed on SEC filing
WM
William McVicarNamed on SEC filing
BB
Brian BloomNamed on SEC filing
EW
Elizabeth WilliamsNamed on SEC filing
SB
Stephanie BrownNamed on SEC filing
MR
Michael RudnickiNamed on SEC filing
BJ
Bill JaroszNamed on SEC filing
AM
Adam MostafaNamed on SEC filing
PD
Philip D. LambertNamed on SEC filing
CW
Courtney WellsNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements

$60.8M disclosed across 6 rounds · 2014–2024

▶$25MraisedJan 2025 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Franklin BergerDirector
  • Frank GleesonExecutive Officer, Director, Promoter
  • Michael Robert CrossExecutive Officer
  • William McVicarDirector
  • Brian BloomDirector
  • Elizabeth WilliamsExecutive Officer
  • Stephanie BrownDirector
  • Michael RudnickiExecutive Officer
  • Bill JaroszDirector
  • Adam MostafaDirector
  • Philip D. LambertExecutive Officer
  • Courtney WellsExecutive Officer
  • Geoff MacKayDirector
  • Rima Al-awarDirector
Offering amount
$25M
Amount sold
$25M
Sales commissions
$1.7M
Placement agents
Haywood Securities (USA) Inc., Canaccord Genuity LLC
First sale
Dec 2024
Incorporated
Corporation, Canada (federal Level), 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$33.3MraisedMay 2023 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William McVicarDirector
  • Frank GleesonExecutive Officer, Director, Promoter
  • Rima Al-awarDirector
  • Geoff MacKayDirector
  • Bill JaroszDirector
  • J. Robert HallExecutive Officer
  • Philip D. LambertExecutive Officer
  • Adam MostafaDirector
  • Brian BloomDirector
  • Warren WhiteheadExecutive Officer
  • Michael RudnickiExecutive Officer
Offering amount
$33.3M
Amount sold
$33.3M
Sales commissions
$2.2M
Placement agents
Haywood Securities (USA) Inc.
First sale
May 2023
Incorporated
Corporation, Canada (federal Level), 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$99.2KraisedSep 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Geoff MacKayDirector
  • Rima Al-awarDirector
  • Bill JaroszDirector
  • Brian BloomDirector
  • William McVicarDirector
  • Michael RudnickiExecutive Officer, Promoter
  • Adam MostafaDirector
  • Frank GleesonExecutive Officer, Director, Promoter
  • J. Robert HallExecutive Officer
  • Warren WhiteheadExecutive Officer
Offering amount
$2.1M
Amount sold
$99.2K
First sale
Sep 2022
Incorporated
Corporation, Canada (federal Level), 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$188KraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • SUSAN KOPPYDirector
  • ANDREW RAEExecutive Officer, Director
  • MICHAEL LIGGETTExecutive Officer, Director
  • WILLIAM JAROSZDirector
Offering amount
$2.5M
Amount sold
$188K
First sale
Aug 2019
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$151.8KraisedMar 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL LIGGETTExecutive Officer, Director
  • PETER HNIKExecutive Officer
  • SUSAN KOPPYDirector
  • WILLIAM JAROSZDirector
  • ANDREW RAEExecutive Officer, Director
Offering amount
$971.7K
Amount sold
$151.8K
First sale
Feb 2019
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedFeb 2014 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Douglas G. JanzenDirector
  • William JaroszDirector
  • W. John MeekisonExecutive Officer
  • Richard BarkerDirector
  • Noel HallDirector
  • Andrew J. RaeExecutive Officer, Director
  • Peter HnikExecutive Officer
Offering amount
$7.9M
Amount sold
$2M
Sales commissions
$266.1K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jan 2014
Incorporated
Corporation, British Columbia, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Satellos do?
Satellos is a biotechnology company developing oral small molecule therapies that restore the body's natural muscle regeneration process by targeting muscle stem cell asymmetric division. Its lead candidate, forazapadin, targets degenerative muscle diseases, beginning with Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy (FSHD).
Who are Satellos's investors?
Satellos's investors include Qiming Venture Partners USA.
How much funding has Satellos raised?
Satellos has disclosed $60.8M raised across 6 rounds.
Where is Satellos headquartered?
Satellos is headquartered in Toronto.